[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366954-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366954-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","emerin-expression-stratification-across-breast-cancer-subtypes","Emerin expression stratification across breast cancer subtypes","","Nuclear dysmorphism functions as a critical marker of tumor aggressiveness, while emerin is an integral nuclear envelope protein required for nuclear integrity and architecture. Prior work linked inverse emerin expression to breast cancer aggressiveness but did not clarify associations with stage, grade, proliferation, or molecular phenotype. This study quantified nuclear-envelope emerin across 243 patient samples, revealing reduced emerin in IDC, ILC, and DCIS versus normal tissue.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/emerin-expression-stratification-across-breast-cancer-subtypes/366954/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/emerin-expression-stratification-across-breast-cancer-subtypes/366954.png","ImageObject",300,407,{"name":42,"@type":43},"acoobca","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about emerin in breast cancer?","Question",{"text":63,"@type":64},"It evaluates whether loss of emerin at the nuclear envelope correlates with cancer stage, grade, proliferation, and molecular phenotype, beyond the general link to aggressiveness.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many breast cancer samples were analyzed, and what was measured?",{"text":68,"@type":64},"The analysis covered 243 patient samples and quantified emerin expression at the nuclear envelope across multiple tumor grades, stages, and molecular phenotypes.",{"name":70,"@type":61,"acceptedAnswer":71},"Which breast cancer subtypes showed reduced emerin expression?",{"text":72,"@type":64},"Reduced emerin was reported in invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and ductal carcinoma in situ (DCIS), compared with normal breast tissue.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366954,1790459218,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Cancer Treat Res Commun. Author manuscript; available in PMC 2026 January 30. |\n| --- | --- |\n\nPublished in final edited form as:  \nCancer Treat Res Commun. 2025 ; 45: 101037. doi:10.1016/j.ctarc.2025.101037 .  \nEmerin expression stratification across breast cancer subtypes Thaysa Ghiaronea,1 , Emily Hansena,b,1 , James M. Holaskaa,b,*  \na Department of Biomedical Sciences, Cooper Medical School of Rowan University, 401 Broadway, Camden, NJ, 08103, USA  \nbMolecular Cell Biology and Neuroscience Program, Rowan-Virtua School of Translational Biomedical Engineering and Sciences, 42 East Laurel Road, Suite 2200, Rowan Medicine Building, Stratford, NJ, 08084, USA  \nAbstract  \nNuclear dysmorphism is a critical indicator of tumor aggressiveness, influencing cancer cell invasion and metastasis. Emerin, an integral nuclear envelope protein involved in nuclear architecture, is important for maintaining nuclear integrity. Our previous work demonstrated an inverse correlation between nuclear envelope-localized emerin expression and breast cancer aggressiveness. However, it failed to have the power to assess whether emerin loss correlates with cancer stage, grade, proliferation, or molecular phenotype. Here we analyzed emerin expression at the nuclear envelope across 243 breast cancer patient samples encompassing various tumor grades, stages, and molecular phenotypes. We found significantly reduced emerin expression in invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and ductal carcinoma in situ (DCIS), compared to normal breast tissue. Notably, emerin loss correlated with advanced tumor stage, higher Ki-67 proliferation rates, elevated human epidermal growth factor receptor 2 (HER2) levels, and decreased estrogen receptor (ER) and progesterone receptor (PR) expression—markers associated with more aggressive breast cancers. Emerin expression was consistently reduced in triple-negative breast cancer (TNBC) and other receptor-negative subtypes, underscoring its potential role in tumor dedifferentiation and progression.  \nThis is an open access article under the CC BY-NC license ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)).  \n*Corresponding author at: Department of Biomedical Sciences, Cooper Medical School of Rowan University, 401 South Broadway, Cam1 Theeena,NJutho, 0rs83ntUSAibuted. oqlaskaually@torowathisnw.eodurk .(J.M. Holaska) .  \nDeclaration of competing interest  \nAll authors have approved this manuscript for submission and have no conflicts of interest to disclose.  \nEthics approval and consent to participate  \nAll datasets have their own ethics approval process through TissueArray LLC, which is where all tissue microarrays were obtained. TissueArray LLC states that all tissue is collected under the highest ethical standards with the donor being informed completely and with their consent; that TissueArray LLC makes sure they follow standard medical care and protect the donors’ privacy; that all human tissues are collected under HIPPA approved protocols; and that all samples were tested negative for HIV and Hepatitis B, and approved for commercial product development. No identifying information is provided with any samples from TissueArray LLC. No clinical data were collected by us during this study, and thus ethics approval was not needed.  \nCRediT authorship contribution statement  \nThaysa Ghiarone: Writing – review & editing, Writing – original draft, Visualization, Software, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Emily Hansen: Writing – review & editing, Writing – original draft, Visualization, Validation, Software, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. James M. Holaska: Writing – review & editing, Writing – original draft, Visualization,","cbCaiiBc8p1FBiuP","https://ap.wps.com/l/cbCaiiBc8p1FBiuP","pdf",1351701,17,"English","# Abstract\n# 1. Introduction","[{\"question\":\"What question does the study address about emerin in breast cancer?\",\"answer\":\"It evaluates whether loss of emerin at the nuclear envelope correlates with cancer stage, grade, proliferation, and molecular phenotype, beyond the general link to aggressiveness.\"},{\"question\":\"How many breast cancer samples were analyzed, and what was measured?\",\"answer\":\"The analysis covered 243 patient samples and quantified emerin expression at the nuclear envelope across multiple tumor grades, stages, and molecular phenotypes.\"},{\"question\":\"Which breast cancer subtypes showed reduced emerin expression?\",\"answer\":\"Reduced emerin was reported in invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and ductal carcinoma in situ (DCIS), compared with normal breast tissue.\"}]","Emerin expression stratification across breast cancer subtypes | PDF",1790168353,43,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a82ad8a98a2fa4054f3e5ae0cce0e6c5.webp",983,1272,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a11fe0316a2d143816f1d22b4a2e33a.webp",982,1270,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57f6de0aa26fbc1c2fa9e3e83d5d726e.webp",981,1269,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e6e930e2d15c949c69ffe801867f1f9.webp",980,1268]